Half of adults who took Jaypirca saw a response to treatment and fewer signs of the disease on their scans.
In a clinical trial that measured the number of people who responded to treatment and how long the response lasted:
OF ADULTS WITH MCL (60 out of 120) saw their cancer shrink and stop spreading while taking Jaypirca
Of the 50%
OF ADULTS (15 out of 120) had a complete response, which means scans and other tests showed no detectable signs of MCL.
OF ADULTS (45 out of 120) had a partial response, which means scans and other tests showed their MCL shrank in response to treatment.
65% were still responding to treatment at 6 months.
For those who saw their MCL shrink and stop spreading, their response lasted a median* of 8.3 months.
*Median is the middle number in a range of numbers.
SELECT SAFETY INFORMATION
Warnings - Jaypirca may cause serious side effects, including:
Infections. Infections can happen during treatment with Jaypirca. These infections can be serious and may lead to death. Your doctor may prescribe vaccines and certain medicines if you have an increased risk of getting infections. Tell your doctor right away if you have fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with Jaypirca.
In a clinical trial, Jaypirca started working quickly, with some people seeing their cancer reduce in size and stop spreading as soon as 3.5 weeks after starting treatment.
In a clinical trial of Jaypirca, the median time for the cancer to shrink and stop spreading with treatment was 1.8 months, ranging from 3.5 weeks at the lowest to 4.2 months at the highest. Median is the middle number in a range of numbers ordered from lowest to highest.
Jaypirca was studied in a clinical trial that included adults with mantle cell lymphoma (MCL) that came back or did not respond to previous treatment and who had already received at least two prior treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine.
Jaypirca was studied in 120 adults with relapsed or refractory† MCL
All people in the study had already received at least 2 treatments for their cancer, including a BTK inhibitor
Trial evaluated response to treatment and how long the response lasted (a response means their cancer shrank and stopped spreading)
Trial participants took Jaypirca once daily until their disease got worse or they were no longer able to tolerate treatment
Learn about taking Jaypirca and possible side effects